A meta-analysis of 48 studies shows GLP-1 receptor agonists have a small but beneficial effect on LV ejection fraction (+ 2.6%) in patients with T2D and cardiovascular disease59. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.